What testosterone dose is appropriate given its oral bioavailability of approximately 86%?

Testosterone Dosing with 86% Oral Bioavailability

If you are considering oral testosterone undecanoate (which has approximately 86% bioavailability when taken with food), start with 225 mg twice daily and titrate by 75 mg per dose at weeks 4 and 8 based on serum testosterone levels, targeting a mid-normal range of 400–700 ng/dL. 1

Understanding Oral Testosterone Bioavailability

• Oral testosterone undecanoate achieves approximately 86% bioavailability when administered with a high-fat meal, making it the only FDA-approved oral testosterone formulation for hypogonadism treatment. 2
• Food is absolutely essential for absorption—fasting administration results in negligible serum testosterone concentrations, whereas co-administration with a standardized meal increases testosterone AUC by more than 10-fold. 2
• Approximately 10% of topically applied testosterone gel is absorbed systemically, producing average steady-state concentrations of 365 ng/dL with 50 mg daily and 612 ng/dL with 100 mg daily. 3

Recommended Dosing Protocol for Oral Testosterone Undecanoate

• Initial dose: 225 mg twice daily (morning and evening) with meals; this regimen achieves eugonadal testosterone concentrations in 87% of patients without requiring dose adjustment. 1
• Titration schedule: Adjust dose by 75 mg increments at weeks 4 and 8 based on average serum total testosterone concentration and maximum observed concentration. 1
• Target serum testosterone: 400–700 ng/dL (mid-normal range), measured 3–6 months after initiation or dose change. 4, 5

Monitoring Requirements

• Measure serum testosterone 3–6 months after starting therapy or any dose change, then every 6–12 months once stable, targeting 400–700 ng/dL. 4, 5
• For oral testosterone undecanoate specifically, obtain the sample 3–5 hours after ingestion to capture peak absorption. 4
• Check hematocrit at baseline, 3–6 months, and annually thereafter; discontinue immediately if hematocrit exceeds 54%. 4, 5
• Obtain baseline PSA and digital rectal exam in men ≥40 years, repeat at 3–6 months, then annually; refer to urology if PSA rises >1.4 ng/mL within 12 months or velocity >0.4 ng/mL/year. 4, 5

Comparison with Injectable Testosterone

• Injectable testosterone cypionate 100 mg weekly provides more stable serum concentrations (avoiding supraphysiologic peaks and subtherapeutic troughs) compared to the traditional 200 mg every 2 weeks regimen. 6
• Annual cost for injectable testosterone is approximately $156 versus $2,135 for transdermal formulations, making intramuscular therapy 13-fold more cost-effective. 7
• Oral testosterone undecanoate offers the convenience of twice-daily dosing without injections, but requires strict adherence to meal timing for adequate absorption. 1, 2

Critical Safety Considerations

• Baseline hematocrit >50% is a relative contraindication because many patients exceed 54% during treatment; a hematocrit >54% mandates immediate cessation. 4, 5
• Active prostate cancer, breast cancer, and untreated severe obstructive sleep apnea are absolute contraindications to any testosterone formulation. 4, 6
• Oral testosterone is teratogenic and not a reliable contraceptive; women who are pregnant or attempting conception must avoid exposure. 8

Enhancing Oral Testosterone Bioavailability

• Co-administration of dutasteride (a 5α-reductase inhibitor) increases oral testosterone bioavailability by 2.7- to 4.6-fold by reducing first-pass hepatic metabolism, though this combination is not FDA-approved. 9, 10
• Curcumin inhibits intestinal UGT2B17 (the enzyme that glucuronidates testosterone) and increases testosterone AUC by 50% and Cmax by 80% in pilot studies, representing a potential future strategy to enhance oral testosterone absorption. 11

Common Pitfalls to Avoid

• Do not prescribe oral testosterone undecanoate without emphasizing mandatory administration with meals—fasting administration results in therapeutic failure. 2
• Do not draw testosterone levels immediately before the next dose for oral formulations; sample 3–5 hours post-ingestion to capture peak absorption. 4
• Do not continue therapy if hematocrit exceeds 54%—this is a hard stop requiring immediate discontinuation and evaluation for hypoxia or sleep apnea. 4, 5